Hepatic ABCA1 and VLDL triglyceride production

Area of Science:

• Lipid Metabolism
• Molecular Biology
• Endocrinology

Background:

• Elevated plasma triglyceride (TG) and reduced high density lipoprotein (HDL) are hallmarks of metabolic syndrome (MS) and type 2 diabetes (T2D).
• Tangier disease, characterized by near absence of HDL and elevated TG, results from mutations in ATP binding cassette transporter A1 (ABCA1).
• ABCA1 facilitates cellular lipid efflux, crucial for nascent HDL particle formation with apolipoprotein A-I (apoA-I).

Purpose of the Study:

• To review the regulation of hepatic very low density lipoprotein (VLDL) triglyceride (TG) production.
• To highlight the connection between hepatic ABCA1 expression and VLDL, LDL, and HDL metabolism.
• To elucidate the role of ABCA1 in the metabolic link between elevated TG and reduced HDL.

Main Methods:

• Analysis of studies on hepatic ABCA1 expression and its impact on lipoprotein metabolism.
• Investigation of ABCA1 function in McArdle rat hepatoma cells (silencing experiments).
• Examination of lipid profiles in hepatocyte-specific ABCA1 knockout (HSKO) mice.

Main Results:

• Silencing ABCA1 in hepatoma cells reduced nascent HDL assembly and increased secretion of TG-enriched VLDL1 particles.
• HSKO mice exhibited a lipid phenotype similar to Tangier disease: elevated VLDL TG, reduced LDL, and significantly lower HDL.
• This phenotype in HSKO mice was attributed to increased VLDL1 secretion, enhanced LDL uptake, impaired HDL assembly, and increased apoA-I catabolism.

Conclusions:

• Hepatic ABCA1 plays a novel, significant role in the metabolism of VLDL, LDL, and HDL.
• ABCA1 deficiency establishes a direct metabolic link between elevated TG and reduced HDL levels.
• These findings offer insights into the pathogenesis of dyslipidemia in Tangier disease, MS, and T2D.